Successful Targeting of an ATG7-RAF1 Gene Fusion in Anaplastic Pleomorphic Xanthoastrocytoma With Leptomeningeal Dissemination

2019 ◽  
pp. 1-7 ◽  
Author(s):  
Mehdi Touat ◽  
Nadia Younan ◽  
Philipp Euskirchen ◽  
Maxime Fontanilles ◽  
Karima Mokhtari ◽  
...  
Keyword(s):  
Gene Fusion ◽  
Pleomorphic Xanthoastrocytoma ◽  
Leptomeningeal Dissemination

scholarly journals RARE-30. ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA WITH LEPTOMENINGEAL DISSEMINATION RESPONSIVE TO BRAF INHIBITION AND BEVACIZUMAB

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi216-vi216 ◽  
Author(s):  
Alissa Thomas ◽  
Suzanne Tucker ◽  
Carl Nelson ◽  
Joshua Nickerson ◽  
Susan Durham ◽  
...  
Keyword(s):  
Pleomorphic Xanthoastrocytoma ◽  
Leptomeningeal Dissemination ◽  
Braf Inhibition

Non-anaplastic pleomorphic xanthoastrocytoma with neuroradiological evidences of leptomeningeal dissemination

2005 ◽  
Vol 22 (6) ◽  
pp. 614-618 ◽  
Author(s):  
Eva Passone ◽  
Stefano Pizzolitto ◽  
Serena D'Agostini ◽  
Miran Skrap ◽  
Maria Paola Gardiman ◽  
...  
Keyword(s):  
Pleomorphic Xanthoastrocytoma ◽  
Leptomeningeal Dissemination

scholarly journals Low-grade spinal glioneuronal tumors with BRAF gene fusion and 1p deletion but without leptomeningeal dissemination

2017 ◽  
Vol 134 (1) ◽  
pp. 159-162 ◽  
Author(s):  
Jason C. H. Chiang ◽  
Julie H. Harreld ◽  
Brent A. Orr ◽  
Suash Sharma ◽  
Azzam Ismail ◽  
...  
Keyword(s):  
Gene Fusion ◽  
Low Grade ◽  
Leptomeningeal Dissemination ◽  
Braf Gene ◽  
1P Deletion ◽  
Glioneuronal Tumors

Anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination responsive to BRAF inhibition and bevacizumab

2018 ◽  
Vol 66 (1) ◽  
pp. e27465 ◽  
Author(s):  
Alissa A. Thomas ◽  
Suzanne M. Tucker ◽  
Carl J. Nelson ◽  
Joshua P. Nickerson ◽  
Susan R. Durham ◽  
...  
Keyword(s):  
Pleomorphic Xanthoastrocytoma ◽  
Leptomeningeal Dissemination ◽  
Braf Inhibition

Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions

2019 ◽  
Vol 19 (5) ◽  
pp. 368-381 ◽  
Author(s):  
Linh N.K. Tran ◽  
Ganessan Kichenadasse ◽  
Pamela J. Sykes
Keyword(s):  
Prostate Cancer ◽  
Valproic Acid ◽  
Androgen Receptor ◽  
Gene Fusion ◽  
Combination Therapies ◽  
Slowing Down ◽  
Castration Resistant ◽  
Local Pca ◽  
End Stage ◽  
Fusion Products

Prostate cancer (PCa) is the most frequent cancer in men. The evolution from local PCa to castration-resistant PCa, an end-stage of disease, is often associated with changes in genes such as p53, androgen receptor, PTEN, and ETS gene fusion products. Evidence is accumulating that repurposing of metformin (MET) and valproic acid (VPA) either when used alone, or in combination, with another therapy, could potentially play a role in slowing down PCa progression. This review provides an overview of the application of MET and VPA, both alone and in combination with other drugs for PCa treatment, correlates the responses to these drugs with common molecular changes in PCa, and then describes the potential for combined MET and VPA as a systemic therapy for prostate cancer, based on potential interacting mechanisms.

Sign in / Sign up

Export Citation Format

Share Document